Edition:
United States

Biosynex SA (ALBIO.PA)

ALBIO.PA on Paris Stock Exchange

3.04EUR
26 Jul 2016
Change (% chg)

€-0.06 (-1.94%)
Prev Close
€3.10
Open
€3.10
Day's High
€3.10
Day's Low
€3.04
Volume
831
Avg. Vol
2,018
52-wk High
€4.21
52-wk Low
€2.17

ALBIO.PA

Chart for ALBIO.PA

About

Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings.... (more)

Overall

Beta: 1.36
Market Cap(Mil.): €19.15
Shares Outstanding(Mil.): 6.18
Dividend: --
Yield (%): --

Financials

  ALBIO.PA Industry Sector
P/E (TTM): -- 43.63 37.05
EPS (TTM): -0.05 -- --
ROI: -2.11 11.61 14.35
ROE: -2.62 13.64 15.56

BRIEF-Biosynex awarded 1 mln euro innovation loan by Bpifrance

* Awarded European Investment Fund innovation loan by Bpifrance to finance deployment of its product

Jul 18 2016

BRIEF-Biosynex finalizes 2 acquisitions

* Finalizes 2 acquisitions which should generate additional annual revenue of 12 million euros ($13.4 million)

Jul 05 2016

BRIEF-Biosynex wins agreement with DRC for order of 10 CellsCheck

* This first order will allow to equip some of the 26 Congolese provinces before the end of 2017 Source text: http://bit.ly/1sO93qZ Further company coverage: (Gdynia Newsroom)

May 24 2016

BRIEF-Biosynex to acquire Fumouze Diagnostics

* Signing of a binding agreement to acquire Fumouze Diagnostics Source text: http://bit.ly/1XlEPGy Further company coverage: (Gdynia Newsroom)

May 18 2016

BRIEF-Biosynex FY net loss narrows to 0.33 million euros

* FY net loss EUR 0.33 million ($372,867.00) versus loss of EUR 1.4 million year ago

Apr 21 2016

BRIEF-Biosynex obtains CE mark for Exacto Pro Test HIV

* Obtains CE mark for rapid serological test new generation of infection by HIV 1 and 2 responsible for AIDS (Exacto Pro Test HIV) Source text: http://bit.ly/215UZVd Further company coverage: (Gdynia Newsroom)

Feb 16 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.